Common use of Orders and Shipments Clause in Contracts

Orders and Shipments. During the term of this Agreement, Molecular Insight Pharmaceuticals will forward orders to Nordion at its Kanata, Ontario facility by facsimile. Each order will set forth the quantity to be produced and shipped, the identity of the recipient, delivery destination protocol number, IND number, applicable USNRC materials license number and IRS number. Delivery of BMIPP to Molecular Insight Pharmaceuticals or as otherwise directed by Molecular Insight Pharmaceuticals shall be FOB transport vehicle at Nordion's facility in Vancouver, British Columbia. Risk of loss of BMIPP shall pass to Molecular Insight Pharmaceuticals at point of delivery. During the term of this Agreement Nordion shall use commercially reasonable best efforts to meet Molecular Insight Pharmaceuticals' orders and delivery requirements. Prior to the first shipment of BMIPP to any third party site, Molecular Insight Pharmaceuticals shall obtain from such third party and provide to Nordion such third party's license evidencing proper legal authority for the receipt and possession of the BMIPP by such third party. Molecular Insight Pharmaceuticals shall obtain all approvals, licenses and permits required to import BMIPP into the United States. Nordion shall make shipping arrangements with AirNet Express or such other carrier designated by Nordion and reasonably approved by Molecular Insight Pharmaceuticals. All shipping costs incurred to deliver BMIPP shall be borne by Molecular Insight Pharmaceuticals. Molecular Insight Pharmaceuticals shall be entitled to cancel any Batch ordered from Nordion by providing to Nordion at least two (2) business days written notice of cancellation prior to the later of commencement of production or the scheduled production date. The failure to give notice hereunder shall result in Molecular Insight Pharmaceuticals being required to pay the full purchase price of such Batch to Nordion. All orders for BMIPP shall be forwarded by Molecular Insight Pharmaceuticals and received by Nordion by the Friday Noon (Eastern time) prior to the week in which BMIPP is to be manufactured.

Orders and Shipments. During the term Term of this Agreement, Molecular Insight Pharmaceuticals will forward orders to Nordion at its KanataOttawa, Ontario facility by facsimilefacsimile or such other method as agreed by the parties. Each order will set forth the quantity of Azedra to be produced and shippedprepared for shipment, the identity of the recipient, delivery destination protocol number, IND IND/NDA number, applicable USNRC materials license number and IRS number. Delivery of BMIPP Azedra to Molecular Insight Pharmaceuticals or as otherwise directed by Molecular Insight Pharmaceuticals shall be FOB transport vehicle Ex Works (Incoterms 2000) at Nordion's ’s facility in VancouverOttawa, British ColumbiaOntario. Risk of loss of BMIPP Azedra shall pass to Molecular Insight Pharmaceuticals at point of deliverydelivery at Nordion’s facility in Ottawa, Ontario. During the term Term of this Agreement Nordion shall use commercially reasonable best efforts to meet Molecular Insight Pharmaceuticals' ’ orders and delivery requirements. Prior to the first shipment of BMIPP Azedra to any third party site, Molecular Insight Pharmaceuticals shall obtain from such third party and provide to Nordion such third party's ’s license evidencing proper legal authority for the receipt and possession of the BMIPP Azedra by such third party. Molecular Insight Pharmaceuticals shall obtain all approvals, licenses and permits required to import BMIPP Azedra into the United States. Nordion shall make shipping arrangements with AirNet Express FedEx or such other carrier designated by Nordion and reasonably approved by Molecular Insight Pharmaceuticals. All Azedra shipping costs incurred to deliver BMIPP from the Ex Works point of delivery shall be borne by Molecular Insight Pharmaceuticals. Molecular Insight Pharmaceuticals shall be entitled to cancel any Batch ordered from Nordion by providing to Nordion at least two (2) business days written notice of cancellation prior to the later of commencement of production or the scheduled production date. The failure to give notice hereunder shall result in Molecular Insight Pharmaceuticals being required to pay the full purchase price of such Batch to Nordion. All orders for BMIPP shall be forwarded by Molecular Insight Pharmaceuticals and received by Nordion by the Friday Noon (Eastern time) prior to the week in which BMIPP is to be manufactured.

Orders and Shipments. During the term Term of this Agreement, Molecular Insight Pharmaceuticals will forward orders to Nordion at its KanataOttawa, Ontario facility by facsimilefacsimile or such other method as agreed by the parties. Each order will set forth the quantity of BMIPP to be produced and shippedprepared for shipment, the identity of the recipient, delivery destination protocol number, IND IND/NDA number, applicable USNRC materials license number and IRS number. Delivery of BMIPP to Molecular Insight Pharmaceuticals or as otherwise directed by Molecular Insight Pharmaceuticals shall be FOB transport vehicle Ex Works (Incoterms 2000) at Nordion's facility in Vancouver, British Columbia. Risk of loss of BMIPP shall pass to Molecular Insight Pharmaceuticals at point of deliverydelivery at Nordion's facility in Vancouver, British Columbia. During the term Term of this Agreement Nordion shall use commercially reasonable best efforts to meet Molecular Insight Pharmaceuticals' orders and delivery requirements. Prior to the first shipment of BMIPP to any third party site, Molecular Insight Pharmaceuticals shall obtain from such third party and provide to Nordion such third party's license evidencing proper legal authority for the receipt and possession of the BMIPP by such * confidential treatment requested * third party. Molecular Insight Pharmaceuticals shall obtain all approvals, licenses and permits required to import BMIPP into the United States. Nordion shall make shipping arrangements with AirNet Express or such other carrier designated by Nordion and reasonably approved by Molecular Insight Pharmaceuticals. All BMIPP shipping costs incurred to deliver BMIPP from the point of delivery transport vehicle Nordion's facility in British Columbia shall be borne by Molecular Insight Pharmaceuticals. Molecular Insight Pharmaceuticals shall be entitled to cancel any Batch ordered from Nordion by providing to Nordion at least two (2) business days written notice of cancellation prior to the later of commencement of production or the scheduled production date. The failure to give notice of cancellation hereunder shall result in Molecular Insight Pharmaceuticals being required to pay the full purchase price of such Batch to Nordion. All orders for BMIPP shall be forwarded by Molecular Insight Pharmaceuticals and received by Nordion by the Friday Noon (Eastern time) prior to the week in which BMIPP is to be manufactured.